Comparison of Classification Standards of BPD in Premature Infants

Wang Jianhui

Status: Unknown

Conditions: Bronchopulmonary Dysplasia

Treatments: Other: no interventions

Study type: Observational

Funder types: Other

Identifiers

NCT04184648

00020191112

Details and patient eligibility

About

Bronchopulmonary dysplasia of premature infants is a common respiratory disease in premature infants. Long-term complications such as recurrent respiratory infection and abnormal lung function may occur in the survivors, and may increase the risk of dysplasia of the nervous system. In the past 30 years, although the monitoring and treatment technology of premature infants has been significantly improved, the incidence of BPD still shows no downward trend, and effective treatment and prevention methods for BPD are still lacking. The progress of clinical research on BPD is slow, one of the important reasons is that the definition of BPD is still not consistent, and its diagnostic and grading standards lack objectivity. To summarize the development of diagnostic criteria for BPD in the past 30 years, there are still the following disadvantages. 1. 2. In the above study, all proposed alternative BPD classification standards did not completely separate HFNC and NIV. In view of this, this study separated HFNC and other NIV to form a new revised BPD classification standard. On this basis, a nested case-control study was conducted to compare the differences between the newly proposed classification standards and NICHD standards in 2001, Rosemary standards in 2018 and Jensen standards in predicting long-term respiratory outcomes and other systemic complications in premature infants, so as to provide a standard for more accurate diagnosis and evaluation of BPD in premature infants.

Enrollment: 200 estimated patients

Sex: All

Ages: Under 32 weeks old

Volunteers: No Healthy Volunteers

Inclusion criteria

• premature infants whose gestational age is less than 32 weeks;
• hospital stay ≥14 days;
• complete clinical medical records, including effective follow-up information

Exclusion criteria

• congenital heart and lung malformation and specific chromosomal diseases;
• children abandon treatment halfway;
• death of children due to factors other than respiratory system.

Trial design

200 participants in 2 patient groups

There was no adverse systems outcome after PMA36 weeks

Description:

Premature infants at PMA36 weeks did not show the following conditions (1) before follow-up tracheotomy; (2) the duration of hospital stay exceeds 50 weeks of PMA; (3) continuous or intermittent use of oxygen and respiratory support for more than 12 months after birth; (4) readmission ≥2 times due to respiratory factors within 12 months. (5) death

Treatment:

Other: no interventions

Death or adverse respiratory outcome after 36 weeks of pma

Description:

Premature infants at PMA36 weeks presented the following conditions (1) before tracheotomy during follow-up; (2) the duration of hospital stay exceeds 50 weeks of PMA; (3) continuous or intermittent use of oxygen and respiratory support for more than 12 months after birth; (4) readmission ≥2 times due to respiratory factors within 12 months. (5) death

Treatment:

Other: no interventions